Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Advanced Cancer Pain Management Market Outlook

The global advanced cancer pain management market is anticipated to attain a valuation of US$ 7,265.44 million in 2023 and is estimated to reach US$ 11,540 million by 2033, trailing a CAGR of 4.74% during the forecast period.

With the rising prevalence of cancer, the awareness for the disease as well as the cancer induced pain is also increasing. This is leading to the increasing healthcare expenditure for diagnosis and therapeutics of the cancer related pain.

According to the Organization for economic cooperation and development, the preliminary estimates of healthcare spending for a group of 16 OECD countries jumped to about 10% of GDP in 2020. Thus, the surging healthcare expenditure and government support across the globe is expected to fuel growth of advance cancer pain management market.

Report Attribute Details
Expected Market Value (2023) US$ 7265.44 million
Anticipated Forecast Value (2033) US$ 11540 million
Projected Growth Rate (2023 to 2033) CAGR 4.74%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Advanced cancer pain treatment Demand Analysis vs. Forecast 2023 to 2033

The industry for advanced cancer pain management recorded a valuation of US$ 6,150 million in 2018, while growing at a CAGR of 3.39 % during the historical period. There are various marketed drugs in the market by several companies. For example, ULTRAM (tramadol hydrochloride) by Janssen Ortho, LLC; Hydromorphone Hydrochrloride by Janssen Korea, Limited, Oxycodone by Taiwan Mundipharma Pharmaceuticals Ltd, and Lazanda (Fentanyl) by Insys Therapeutics, Inc., among others. These drugs are expected to present growth opportunities for the market of advanced cancer pain treatment in the upcoming years.

Various market players are also investing in research and development activities for development of more effective drugs for the treatment of advanced cancer pain. Some of these emerging drugs include Morphine sulfate by Tetra Biopharma/Cognitive Research Corporation, Resiniferatoxin by Sorrento Therapeutics, Inc., and Pregabalin by Institut Cancerologie de l'Ouest/Grunenthal GmbH. Likewise, Sorrento's resiniferatoxin received Food and drug administration’s clearance for proceeding with its Phase two clinical study for using epidural resiniferatoxin as a therapeutic medicine for intractable pain related with advanced cancer.

On the other hand, Patients suffering from advanced or metastatic cancer cannot be treated for cancer pain only with analgesics. They require invasive techniques like peripheral nerve blockers and neuraxial analgesia for vertebral pain, among others. Surging advancements in nerve blockers to improve pain control and offer long-term relief to advanced cancer patients are also anticipated to drive market revenue growth during the forecast period. Considering the above-mentioned factors and new developments, the revenue growth of Advanced cancer pain treatment market is projected to be worth US$ 11,540 million by end of the forecast period, while exhibiting a CAGR of 4.74%.

Which are Some Prominent Drivers spearheading the Advanced Cancer Pain Management Market?

Availability of effective therapies and increasing healthcare expenditure driving market growth

The growth of the global advanced cancer pain treatment market is primarily driven by rising prevalence of cancer; growth in geriatric population, increasing healthcare expenditure and mounting investments in research and development activities by various healthcare companies. For example, according to American Cancer Society, nearly 1.80 million new cancer cases were diagnosed and about 606,525 cancer deaths were observed in the United States, in 2020. Also, according to the International Agency for Research on Cancer, approximately 1,065,960 new cases were reported for colorectal cancer worldwide in 2020. This rising trend in cancer cases will create market space for the expansion of cancer pain management market during the forecast period.

The geriatric population is more susceptible to various types of cancers, such as lung cancer, renal cancer, bladder cancer, melanoma, and others, owing to aging effect and mutation in the gene. According to the National Cancer Institute, the average age for diagnosis is 60 years for breast cancer, 67 years for colorectal cancer, 70 years for lung cancer, and 66 years for prostate cancer. Moreover, according to the Medicare and Medicaid Services, the National Health Expenditure reached $3.80 trillion in 2019. The National health expenditure increased by 4.6% in 2019, and accounted for approximately 17.7% of the United States GDP. Increase in demand for monoclonal antibodies for the treatment of cancer induced pain is also expected to boost growth of the advanced cancer pain market.

Also, availability of effective therapies and growing focus on relieving advanced cancer pain are leading to advancements in understanding the etiology and pathophysiology of cancer pain that is benefiting the market. Furthermore, surging investments and efforts to develop comprehensive approach to classify cancer pain due to growing emphasis on proper management and treatment of advanced cancer pain are also anticipated to drive market growth during the forecast period.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the challenges expected to be Faced by the Market?

Adverse effects to restrain market growth

Side-effects associated with the use of drugs employed in cancer pain treatment such as drug tolerance, dependence on drugs, urinary retention, sleep disorders, cognitive impairment, and others are anticipated to hamper the cancer pain market growth over the forecast period.

Also, dearth of awareness among clinicians in effective management of cancer pain, absence of opioids in developing countries, and dearth of established healthcare infrastructure in low- and middle-income countries are some key factors anticipated to restrain market growth during the forecast period.

Region-Wise Insights

What are the growth prospects in North America?

North America dominates the market with maximum share

North America is expected to dominate the market of Advanced cancer pain treatment by accounting for 42.9% market share by end of the forecast period. This region is anticipated to retain its dominance during the forecast period, due to growing prevalence of cancer, technological advancements in healthcare, easy access and availability of pain therapeutics, and availability of better-quality chemotherapy treatment options.

The growth in this region is also attributed to favorable healthcare infrastructure, which encourages easy access to advanced pain management devices. Furthermore, rising government initiatives, like Precision Medicine and Affordable Care Act, along with a well-planned reimbursement policy in this region is supporting market growth. The regional market is also propelled by the presence of robust healthcare facilities, surging aging population, and rising incidences of hypertension and stroke. With the increase in elderly population, the market is anticipated to show a higher growth rate, as the elder population is at greater risk of severe illness. Thus, leading to market growth in the region.

What is the growth outlook in Asia Pacific?

Asia Pacific driving growth with fastest CAGR

The market in Asia Pacific is projected to exhibit fastest CAGR of 5.5% during the forecast period. The growth is attributable to increasing incidence of cancer, rapid advancements in cancer research, development of strong therapeutic pipeline, easy availability of advanced cancer drugs, and growing focus on palliative and end-of-life care.

This growth can also be attributed to research and developments investments in producing technologically advanced healthcare therapeutic options. Furthermore, the presence of numerous trade agreements is also leading to market growth in the region. For example, the Asia Pacific Trade Agreement between China, India, Bangladesh, Lao PDR, Republic of Korea, Mongolia, and Sri Lanka has encouraged trade liberalization and increased import and export opportunities amongst participating nations. This will lead to market growth in this region.

In addition, strengthening of healthcare infrastructure, growing per capita income, increasing geriatric population, and increasing prevalence of advance chronic pain in the region is leading to market growth. According to the United Nations Department of Economic and Social Affairs report on world population aging, the number of elderly people in Asia is anticipated to increase by two-fold, from 394 million in 2019 to 588 million by 2030. Elderly people are at a greater risk of chronic pain conditions, like arthritis, neuropathic disorders, and back pain, which, in turn, drives the demand for drugs and devices for the treatment of chronic pain including cancer pain.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category wise Insights

By Drug Class, Which Segment will possess Market Hegemony?

Cannabinoids driving growth with significant market share

The cannabinoids segment dominated the market in 2021, and is anticipated to continue the trend during the forecast period by reaching market share of 35% by end of the forecast period. The growth is attributed to rising prevalence of severe cancer pain, surge in adoption of cannabinoids in the treatment of cancer pain, and robust presence of pipeline drugs.

A significant number of patients are turning to cannabis and cannabinoids for management of their palliative and nonpalliative cancer pain and other cancer-associated symptoms which is expected to drive growth of this segment.

A cohort study using ‘nabiximols’ on advanced cancer pain in patients already using opioids, over 3 weeks, showed improved average pain score. A large observational study of cancer patients using cannabis over 6 months showed a reduced number of patients with acute pain and reduced opioid use, whereas the number of patients reporting good quality of life were increased. Good preclinical animal data and a vast body of observational evidence point to the potential effectiveness of cannabinoids for cancer pain treatment.

Which segment will dominate the market by route of administration?

Intravenous segment driving industry growth with dominating share

This segment is anticipated to dominate the market of advance cancer pain management market by accumulating a market share of 78% by end of the forecast period. This segment is also expected to grow with fastest CAGR of 8.9% during the forecast period. Intravenous administration offers various advantages like high bioavailability of pain medications, better dose control and administration rate, and generation of stable pharmacodynamics and pharmacokinetics profiles. This is anticipated to boost adoption of intravenous route of administration during cancer pain management therapies. Also, intravenous administration of morphine allows better management of pain in patients suffering from severe cancer pain, for breakthrough pain, and in patients with weak pain control under high opioid dosages, which is anticipated to further boost revenue growth of the segment during the forecast period.

By Distribution Channel, which segment is expected to dominate the market?

Hospital Pharmacies to drive growth with maximum market share

Hospital pharmacies are expected to dominate the market of advance cancer pain management by reaching 67.2% market share by end of the forecast period. This segment is also anticipated to grow with fastest CAGR of 7.6% during the projected period. Factors such as growing preference and trust of suffered patients towards hospital environments, government focus on strengthening healthcare infrastructure, easy access to treatment facilities are some factors leading to the growth of this segment. Furthermore, the drugs developed by various industry companies after intense research and development activities directly benefits the hospital pharmacies. This will also contribute to expansion of this segment in the forecast period.

Start-ups in Advanced cancer pain management market

Start-ups help in determining the future growth opportunities in any market. These new entrants have the potential to generate high returns which directly benefits the expansion of any industry. These start-ups are typically more efficient at transforming inputs into outputs with more flexibility and adaptability in nature, able to shift quickly in response to sensitive market conditions. Some of the start-ups that will bolster the expansion of Advanced cancer pain management market are:

  • ‘Grow Group’ is a London, United Kingdom-based developer of cannabis-based medicines for multiple indications. It was founded in 2017. This start-up discovers and develops cannabis-based medicine for treating chronic pain like neuropathic pain, cancer induced pain, epileptic seizures, spasticity, and drug addictions. It also provides Calyx app to track health, medicine, and activities. It was granted funding of USD 13 million.
  • ‘ZYUS life sciences’ is a Saskatoon, Canada-based start-up that develops cannabis-derived therapeutics for multiple indications. It was founded in 2018. This company is focusing on developing cannabinoid-based therapeutics and protein-based formulations to provide targeted relief for patients. The lead drug candidate of the company is Trichomylin which alleviates chronic pain. This start-up gathered a funding of USD 20 million from ‘Keyhorse Capital’
  • Founded in 2012, ‘Junshi Biopharma’ is a Shanghai based start-up that offers antibody-based therapeutics for multiple diseases. The drug candidates of this company include anti-PD-1 monoclonal antibodies, PCSK9 monoclonal antibodies, anti-BLyS monoclonal antibodies, and few others for treatment of cancer, metabolic, neurology, immunology, and infectious diseases. It received funding of USD 31.5 million in 2018.

Market Competition

The advanced cancer pain management market is extremely competitive and consists of several industry players. These players are developing novel delivery systems for treating Advanced cancer pain management. This is estimated to propel advanced cancer pain management market. The key players in this industry are: WEX Pharmaceuticals Inc, Jazz Pharmaceuticals, Nobelpharma Co., Ltd, Tetra Bio-Pharma Inc., Pfizer, Recipharm, eurofins, Sigma-Aldrich, AstraZeneca, GlaxoSmithKline plc. Key market players are tending towards adoption of inorganic growth strategies like acquisition, mergers, partnerships, and collaboration in order to strengthen their product portfolio. This is anticipated to fuel the global Advanced cancer pain management market.

  • In October 2022, Parker Laboratories Inc., which develops, manufactures, and sells pain relief creams, ultrasound and electromedical contact media, and institutional cleaners and disinfectants, is increasing its analgesics line. The company has added Helix CBD Therapy Cream, CBD Clinical Cream, and Tri-Active Therapy Cream to its HelixTM line.
  • In September 2022, Compass Group Equity Partners which is a St. Louis-based private equity firm, declared a strategic partnership with Mays & Schnapp Neurospine and Pain ("Mays & Schnapp"), based in Memphis, interventional pain management practice serving patients in Tennessee and Mississippi.
  • In July 2021, Venus Remedies Limited announced launch of a consumer healthcare division that will provide various products for pain management.
  • In January 2021, Boston Scientific Corporation announced the launch of Wave Writer Alpha, a portfolio of spinal cord stimulator systems that combine therapy options for personalized pain relief.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 7,265.44 million
Market Value in 2033 US$ 11,540 million
Growth Rate CAGR of 4.74% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Drug Class
  • Route of Administration
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • China
  • Japan
  • Indonesia
  • Singapore
  • Thailand
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • WEX Pharmaceuticals Inc.
  • Jazz Pharmaceuticals
  • Nobelpharma Co., Ltd
  • Tetra Bio-Pharma Inc.
  • Pfizer
  • Recipharm
  • eurofins
  • Sigma-Aldrich
  • AstraZeneca
  • GlaxoSmithKline plc
Customization Available Upon Request

Key Segments Profiled in the Advanced Cancer Pain Management Industry Survey

By Drug Class:

  • Monoclonal Antibody
  • Cannabinoid
  • Aminoindane

By Route of Administration:

  • Intravenous
  • Oral
  • Inhalational

By Distribution Channel:

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Frequently Asked Questions

What is Current Market Valuation of Advanced Cancer Pain Management?

The market is estimated to secure a valuation of US$ 7,265.44 million in 2023.

How Big will be the Advanced Cancer Pain Management Market by 2033?

The market is estimated to reach US$ 11,540 million by 2033.

What Limits the Growth Potential of the Market?

Side-effects of using drugs is likely to limit market growth.

Who are the Key Advanced Cancer Pain Management Market Players?

WEX Pharmaceuticals Inc., Jazz Pharmaceuticals, and Nobelpharma Co., Ltd are key advanced cancer pain management market players.

Which is the Effective Market Strategy?

Players develop novel delivery systems to enhance their market competitiveness.

Table of Content

1. Executive Summary | Advanced Cancer Pain Management Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. Monoclonal Antibody

        5.3.2. Cannabinoid

        5.3.3. Aminoindane

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        6.3.1. Intravenous

        6.3.2. Oral

        6.3.3. Inhalational

    6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Pharmacies

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. MIDDLE EAST AND AFRICA

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Drug Class

        9.2.3. By Route of Administration

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Route of Administration

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Class

        10.2.3. By Route of Administration

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Route of Administration

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Drug Class

        11.2.3. By Route of Administration

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Route of Administration

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

            12.2.1.4. Singapore

            12.2.1.5. Thailand

            12.2.1.6. Indonesia

            12.2.1.7. Australia

            12.2.1.8. New Zealand

            12.2.1.9. Rest of Asia Pacific

        12.2.2. By Drug Class

        12.2.3. By Route of Administration

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Route of Administration

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. MIDDLE EAST AND AFRICA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MIDDLE EAST AND AFRICA

        13.2.2. By Drug Class

        13.2.3. By Route of Administration

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Route of Administration

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. Key Countries Market Analysis

    14.1. USA

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2022

            14.1.2.1. By Drug Class

            14.1.2.2. By Route of Administration

            14.1.2.3. By Distribution Channel

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2022

            14.2.2.1. By Drug Class

            14.2.2.2. By Route of Administration

            14.2.2.3. By Distribution Channel

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2022

            14.3.2.1. By Drug Class

            14.3.2.2. By Route of Administration

            14.3.2.3. By Distribution Channel

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2022

            14.4.2.1. By Drug Class

            14.4.2.2. By Route of Administration

            14.4.2.3. By Distribution Channel

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2022

            14.5.2.1. By Drug Class

            14.5.2.2. By Route of Administration

            14.5.2.3. By Distribution Channel

    14.6. United Kingdom

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2022

            14.6.2.1. By Drug Class

            14.6.2.2. By Route of Administration

            14.6.2.3. By Distribution Channel

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2022

            14.7.2.1. By Drug Class

            14.7.2.2. By Route of Administration

            14.7.2.3. By Distribution Channel

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2022

            14.8.2.1. By Drug Class

            14.8.2.2. By Route of Administration

            14.8.2.3. By Distribution Channel

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2022

            14.9.2.1. By Drug Class

            14.9.2.2. By Route of Administration

            14.9.2.3. By Distribution Channel

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2022

            14.10.2.1. By Drug Class

            14.10.2.2. By Route of Administration

            14.10.2.3. By Distribution Channel

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2022

            14.11.2.1. By Drug Class

            14.11.2.2. By Route of Administration

            14.11.2.3. By Distribution Channel

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2022

            14.12.2.1. By Drug Class

            14.12.2.2. By Route of Administration

            14.12.2.3. By Distribution Channel

    14.13. Singapore

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2022

            14.13.2.1. By Drug Class

            14.13.2.2. By Route of Administration

            14.13.2.3. By Distribution Channel

    14.14. Thailand

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2022

            14.14.2.1. By Drug Class

            14.14.2.2. By Route of Administration

            14.14.2.3. By Distribution Channel

    14.15. Indonesia

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2022

            14.15.2.1. By Drug Class

            14.15.2.2. By Route of Administration

            14.15.2.3. By Distribution Channel

    14.16. Australia

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2022

            14.16.2.1. By Drug Class

            14.16.2.2. By Route of Administration

            14.16.2.3. By Distribution Channel

    14.17. New Zealand

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2022

            14.17.2.1. By Drug Class

            14.17.2.2. By Route of Administration

            14.17.2.3. By Distribution Channel

    14.18. GCC Countries

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2022

            14.18.2.1. By Drug Class

            14.18.2.2. By Route of Administration

            14.18.2.3. By Distribution Channel

    14.19. South Africa

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2022

            14.19.2.1. By Drug Class

            14.19.2.2. By Route of Administration

            14.19.2.3. By Distribution Channel

    14.20. Israel

        14.20.1. Pricing Analysis

        14.20.2. Market Share Analysis, 2022

            14.20.2.1. By Drug Class

            14.20.2.2. By Route of Administration

            14.20.2.3. By Distribution Channel

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Drug Class

        15.3.3. By Route of Administration

        15.3.4. By Distribution Channel

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. WEX Pharmaceuticals Inc

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. Jazz Pharmaceuticals

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. Nobelpharma Co., Ltd.

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Tetra Bio-Pharma Inc.

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Pfizer

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Recipharm

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. eurofins

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. Sigma-Aldrich

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. AstraZeneca

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. GlaxoSmithKline plc

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Recommendations

Healthcare

Cancer Diagnostics Market

Published : August 2023

Healthcare

Central Pain Syndrome Management Market

Published : January 2023

Healthcare

Pain Management Devices Market

Published : October 2022

Healthcare

Cancer Supportive Care Products Market

Published : July 2020

Explore Healthcare Insights

View Reports

Advanced Cancer Pain Management Market